The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC), allowing it ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback